HEALTHEQUITY INC

HealthEquity insider sale: Gathright sells 2,270 shares at $93.07—routine “sell‑to‑cover” amid rising platform earnings. Discover what this means for investors.

HealthEquity insider selling: EVP Michael Fiore’s recent 3,142‑share sale signals steady executive divestment, yet the company’s fundamentals and growth outlook remain intact.

HealthEquity insider activity: EVP Rajasekar Sunil holds RSUs while top execs sell – a contrast that signals confidence in future growth and potential market impact.

HealthEquity’s CTO exit sparks insider selling and investor uncertainty: analyze the impact on tech strategy, share price, and future growth.

HealthEquity CEO Cutler Scott sells 4,931 shares on a quiet day—no distress, just routine liquidity amid a CTO change.

HealthEquity insider sale: founder sells 2,559 shares amid CTO exit, but long‑term stake stays strong—insider activity, tech shift, and market reaction explained.

Delano’s March 31 HealthEquity share sale shows disciplined short‑term liquidity tactics amid steady fundamentals, reassuring investors that management remains confident in the company’s growth.

HealthEquity insider sale: founder Stephen Neeleman sold 9,292 shares at $82.53 – a routine move that signals long‑term confidence amid strong fundamentals and a growing health‑savings platform.

HealthEquity insider buying signals reveal executive confidence and potential upside ahead – discover what recent purchases mean for investors and future growth.

HealthEquity insider selling: CEO and execs sell shares amid 2027 outlook—why it matters for investors and what it signals about future growth.